文献速递造血干细胞移植与细胞治疗淋巴瘤白血病

将EF1α驱动的CD7特异性CAR插入CD7基因座可减少自相残杀并增强肿瘤排斥

Inserting EF1α-driven CD7-specific CAR at CD7 locus reduces fratricide and enhances tumor rejection.
PubMed 文献 · Leukemia · 2023-06-30

本研究开发了一种2合1策略,利用CRISPR/Cas9将EF1α驱动的CD7特异性CAR插入被破坏的CD7基因座,并与逆转录病毒随机整合CAR和TRAC位点特异性整合CAR两种策略进行比较。三种CD7 CAR-T细胞均能良好扩增并对CD7+肿瘤细胞系及患者原代肿瘤显示强细胞毒性;EF1α驱动的CAR在CD7基因座表达可增强小鼠T-ALL异种移植模型中的肿瘤排斥。该策略还可用于生成CD7特异性CAR-NK细胞。

要点

  • 2合1策略将EF1α驱动的CD7 CAR插入CD7基因座,减少自相残杀。
  • 三种CD7 CAR-T细胞均能良好扩增并具强细胞毒性。
  • CD7基因座表达的EF1α驱动CAR增强小鼠T-ALL模型肿瘤排斥。

核心结论

  • 同步抗原敲除与CAR敲入策略可减少自相残杀并增强抗肿瘤活性,推进T细胞恶性肿瘤的临床CAR-T治疗。

研究设计与样本

  • 研究利用CRISPR/Cas9敲除CD7,并将EF1α驱动的CD7特异性CAR插入被破坏的CD7基因座,与逆转录病毒随机整合CAR及TRAC位点特异性整合CAR两种策略进行比较。

主要发现

  • 三种CD7 CAR-T细胞均能良好扩增,并对CD7+肿瘤细胞系和患者来源原代肿瘤显示强细胞毒性。
  • EF1α驱动的CAR在CD7基因座表达增强小鼠T-ALL异种移植模型中的肿瘤排斥。
  • 该2合1策略被用于生成CD7特异性CAR-NK细胞,以防止恶性细胞污染。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CAR-T therapies to treat T-cell malignancies face unique hurdles. Normal and malignant T cells usually express the same target for CAR, leading to fratricide. CAR-T cells targeting CD7, which is expressed in various malignant T cells, have limited expansion due to fratricide. Using CRISPR/Cas9 to knockout CD7 can reduce the fratricide. Here we developed a 2-in-1 strategy to insert EF1α-driven CD7-specific CAR at the disrupted CD7 locus and compared it to two other known strategies: one was random integration of CAR by a retrovirus and the other was site-specific integration at T-cell receptor alpha constant (TRAC) locus, both in the context of CD7 disruption. All three types of CD7 CAR-T cells with reduced fratricide could expand well and displayed potent cytotoxicity to both CD7+ tumor cell lines and patient-derived primary tumors. Moreover, EF1α-driven CAR expressed at the CD7 locus enhances tumor rejection in a mouse xenograft model of T-cell acute lymphoblastic leukemia (T-ALL), suggesting great clinical application potential. Additionally, this 2-in-1 strategy was adopted to generate CD7-specific CAR-NK cells as NK also expresses CD7, which would prevent contamination from malignant cells. Thus, our synchronized antigen-knockout CAR-knockin strategy could reduce the fratricide and enhance anti-tumor activity, advancing clinical CAR-T treatment of T-cell malignancies.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Jiang J, Chen J, Liao C, et al. Inserting EF1α-driven CD7-specific CAR at CD7 locus reduces fratricide and enhances tumor rejection. Leukemia. 2023. PMID: 37391486. doi:10.1038/s41375-023-01948-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。